Track topics on Twitter Track topics that are important to you
MONTREAL, March 26, 2019 (GLOBE NEWSWIRE) -- I-MED Pharma, Inc., a Canadian company specializing in dry eye diagnosis and management, announced today the signing of an exclusive agreement with DryCom - Dry Eye Solutions for distribution of its I-PEN® Tear Osmolarity System in Brazil.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/293fa361-658c-4d57-9766-cc16edfa5498
The I-PEN® is the world’s first, point-of-care, electronic diagnostic testing device to detect and indirectly measure the tear film osmolarity levels associated with marginal, mild, moderate and severe dry eye disease. The I-PEN® Osmolarity System, used in conjunction with the I-PEN® Osmolarity Single-Use-Sensors (SUS), provides a quick and simple method for determining tear osmolarity from the tear soaked palpebral conjunctiva.
Daniel Hofmann, President of I-MED Pharma, stated, “DryCom is a promising partner for us, with a unique vision for expanding access of our cutting-edge products to both eye care professionals and dry eye patients in the Brazilian market. We are excited by the opportunity present in this country and will be working closely with DryCom to launch the I-PEN® Osmolarity System in the upcoming months.”
Gustavo Couri, CEO of DryCom, commented, “DryCom is excited to announce the imminent launch of the I-PEN® in Brazil. The I-PEN® osmolarity device will now allow medical professionals in the industry to diagnose their patients with the most modern and cost-effective tool for dry eye.”
I-MED Pharma is a privately held Canadian company, headquartered in Montreal, Quebec, servicing Canadian ophthalmologists, optometrists and the global eye care community. Established thirty years ago, I-MED Pharma Inc. creates and distributes innovative medical, surgical and veterinary eye care products. It continually researches, develops and sources the most effective and advanced solutions to eye disorders like cataracts, corneal degenerations, glaucoma, dry eye and meibomian gland disease.
I-MED Pharma is proud to have been at the forefront of managing Dry Eye Syndrome as a serious disease and invests heavily in researching and developing effective dry eye products. I-MED Pharma’s ocular surface disease product range includes dry eye drops, ocular hygiene, nutrition, therapeutic accessories and ocular occlusion devices.
DryCom was founded exclusively to identify and offer to ophthalmic professionals the most current, innovative solutions for patients with Dry Eye Disease. DryCom is a company dedicated to bringing cutting-edge diagnostics and treatments to dry eye patients.
Additional photos accompanying this announcement are available at:NEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Surgery is a technology consisting of a physical intervention on tissues. All forms of surgery are considered invasive procedures; so-called "noninvasive surgery" usually refers to an excision that does not penetrate the structure being exci...